Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.
Biotech rules and bonds disappoint for many Morningstar.com readers.
Fidelity's growth-leaning equity funds and more conservative bond funds made for a strong year for the fund firm, says Morningstar analyst Katie Reichart.
International opportunities, income, and M&A activity were on investors' minds in September.
Funds that held up better than their peers in 2008 soon may not compare as favorably, as five-year returns move forward.